What is PROK's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.53B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PROK?

P/E (TTM) is n/a and 52-week range is $1.30 to $3.48 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PROK figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PROK?

The company profile lists revenue (TTM) near $1M, net income (TTM) near $-13.67B, EPS (TTM) near $-0.55 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Prokidney Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Winston-Salem, North Carolina, US, 302.1M shares outstanding, ISIN US74291D1046 when available from company profile and filing metadata.

Prokidney Corp

$PROK

Health Care · Biotechnology

IR Run Scenarios

$1.74

+4.82%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 231 full-time employees. The company went IPO on 2021-06-30. The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.

Employees

231

Website

prokidney.com/

IPO

2021-06-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)